GlassScriptPhysician profile
Aditya Multanmal Sharma
NPI 1265631931
$40,886.20
in general payments reported to CMS, 2019-2025
13 companies · $19K in 2025
The $19K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2021: $6,838 · 2022: $3,028 · 2023: $5,406 · 2024: $6,072 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,600 · Food and Beverage: $2,905 · Travel and Lodging: $2,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,020.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,600.00 |
| Food and Beverage | $2,904.68 |
| Travel and Lodging | $2,277.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $19,469.89 | 2021-2025 | General - Therapies, Ekosonic, General - Angiography |
| E.R. Squibb & Sons, L.L.C. | $13,352.59 | 2025 | |
| Novartis Pharmaceuticals Corporation | $5,396.50 | 2024-2025 | |
| Medtronic, INC. | $1,329.55 | 2023-2025 | Venaseal, Symplicity G3 |
| Neurocrine Biosciences, INC. | $332.63 | 2025 | |
| Stryker Corporation | $276.86 | 2025 | Flowtriever |
| Kestra Medical Technology Services, INC. | $193.11 | 2025 | Assure Wcd |
| W. L. Gore & Associates, INC. | $148.66 | 2019 | |
| Angiodynamics, INC. | $126.98 | 2022 | |
| Cardiva Medical, INC. | $114.62 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Thrombolex, INC. | $76.01 | 2023 | |
| Integra Lifesciences Corporation | $57.73 | 2019 | |
| Allergan, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditya Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.